A newly approved drug is available to reverse the blood-thinning effects of dabigatran, marketed as Pradaxa, in emergency or life-threatening situations when bleeding can’t be controlled. Idarucizumab, sold under the brand name Praxbind, binds specifically to dabigatran molecules and neutralizes…
Sourced through Scoop.it from: jama.jamanetwork.com
Noticias de la Food and Drug Administration
